Drivers of this market include the increase in sedentary and unhealthy lifestyles, resulting in higher rates of deep vein thrombosis (DVT), peripheral artery disease, acute myocardial infarction, and pulmonary embolism (PE). Other factors are a growing geriatric population and advanced medical technology improvements that allow stroke to be treated quickly and more effectively, with improved patient outcomes and shorter hospital stays.
“Over the past decade, advancements in technologies have allowed for the development of safer, quicker, and more efficient clot removal in both large and small vessels,” said James F. Benenati, chief medical officer at Penumbra, an Alameda, Calif.-based global healthcare company focused on innovative therapies for stroke, peripheral and coronary blood clots, and aneurysms. “These advancements have shortened the t
Continue reading this story and get 24/7 access to Medical Product Outsourcing for FREE
Our in-depth coverage includes comprehensive feature articles, industry news, trends, and other developments pertinent to the service provider-OEM relationship. MPO examines the increasingly complex and demanding requirements of managing outsourcing partnerships. From regulatory mandates and manufacturing best practices to market shifts and legal concerns, our website is filled with exclusive content to help device manufacturers and their vendors stay informed. Join Today!
FREE SUBSCRIPTION